Advertisement

Topics

Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines

08:10 EST 7 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
SAKURA Program Topline Results on Track to Report Fourth Quarter 2017 Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, to...

Other Sources for this Article

Investors:
Revance Therapeutics
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

NEXT ARTICLE

More From BioPortfolio on "Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines"

Advertisement
Quick Search
Advertisement
Advertisement